Urology Product PreviewDrugs and devices in the pipeline from Targacept, Inc., Cubist, OncoGenex Pharmaceuticals, Inc., Apricus Biosciences, and Nymox Pharmaceutical Corp.
Best of AUA 2013: BPH/LUTSBruce R. Kava, MD, presents the take home messages on BPH/LUTS from the AUA annual meeting in San Diego.
Reduced OR, laser time observed with newer PVP systemThe new-generation GreenLight XPS-180W laser system (American Medical Systems, Minnetonka, MN) achieved an improved rate of tissue vaporization and overall efficacy in patients with BPH compared to an earlier generation laser, according to results of a recent multicenter study.
Nerve injury during sling procedure prompts suitIn this case, the woman claimed her damages from the negligent nerve injury included pain and weakness in her legs and a second operation to replace the sling.
AUA 2013: ‘Lift’ procedure shows durable improvement in LUTSMen with symptomatic BPH had statistically significant, durable improvement in lower urinary tract symptoms (LUTS) following an office-based, minimally invasive prostatic urethral lift procedure, results of a pivotal randomized trial showed.
Evolving algorithm for treating male voiding symptomsThe algorithm for urologists’ approach to male voiding symptoms is evolving, according to Steven A. Kaplan, MD, of Weill Cornell Medical College, New York. This will be evident in presentations on BPH and lower urinary tract symptoms at the AUA annual meeting.
Embolization may offer less-invasive option for BPHMen with BPH may obtain symptomatic relief with minimally invasive prostatic artery embolization (PAE), according to results from a small, prospective study.
Study questions botulinum’s efficacy in post-BPH overactive bladderIntradetrusor injections of onabotulinumtoxinA (Botox) do not significantly reduce urinary frequency in patients with refractory overactive bladder secondary to BPH, results from a two-institution, placebo-controlled study indicate.